Joint Formulary & PAD

Liraglutide - Diabetes Mellitus

You are here : Home > Formulary Search > Liraglutide - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Preferred

Documentation

Patient resource
GLP-1 patient agreement form - February 2018
Information
GLP-1 medicines for weight loss and diabetes: what you need to know - MHRA guidance
Information
Antidiabetic treatments comparison- PrescQIPP resource - February 2018

PAD Profile

ChemicalSubstance :
Liraglutide
Indication :
Diabetes Mellitus
Group Name :
GLP-1s
Keywords :
GLP-1s, GLP1s, GLP 1s, glucagon like peptide-1, blood glucose lowering drugs, Type II
Brand Names Include :
Victoza, Diavic, Zegluxen, Liraglutide Biocon
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Diabetes Mellitus
Supporting Documents :
3

Committee Recommendations (2)

01 Oct 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Dose titration for weight loss in diabetes:

The Surrey Heartlands Integrated Care System Area Prescribing Committee agree the following for the GLP1s (semaglutide, tirzepatide and liraglutide), when used for diabetes:

  • Continue at 6 months only if HbA1c has reduced by at least 11mmol/mol (1%) and weight reduction of at least 3%
  • Further dose titrations after 6 months should be in line with glycaemic control only, unless the patient meets the cohort criteria for weight management for

o   Semaglutide: joint-position-statement-on-medical-therapies-for-obesity_final-resubmitted-sfe-211223.pdf

o   Tirzepatide: PRN01879-interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-NICE-fu.pdf

o   Liraglutide: 1 Recommendations | Liraglutide for managing overweight and obesity | Guidance | NICE

01 Oct 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

At the October 2025 APC, it was agreed to remove any recommendation of a preferred GLP-1 mimetic

Other Indications

Below are listed other indications that Liraglutide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.